T-Oligos inhibit growth and induce apoptosis in human ovarian cancer cells

Oligonucleotides

Volumn 21, Issue 1, 2011, Pages 47-53

  Sarkar, Sibaji ^a   Faller, Douglas V ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OLIGOSACCHARIDE; T OLIGO; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CELL CYCLE PROGRESSION; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL; SEQUENCE HOMOLOGY; TELOMERE;

APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; FLOW CYTOMETRY; HISTONE DEACETYLASE INHIBITORS; HUMANS; MOLECULAR MIMICRY; MOLECULAR TARGETED THERAPY; NEOPLASMS, GLANDULAR AND EPITHELIAL; OLIGONUCLEOTIDES; OVARIAN NEOPLASMS; TELOMERE;

EID: 79951836778     PISSN: 15454576     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.2010.0259     Document Type: Article

References (22)

1. 0 overhang-specific DNA oligonucleotides induce autophagy in malignant glioma cells. FASEB J. 21, 2918-2930. (Pubitemid 47372758)
2. 0 overhang specific DNA. FASEB J. 17, 152-162. (Pubitemid 36164385)
3. ELLER, M.S., MAEDA, T., MAGNONI, C., ATWAL, D., and GILCHREST, B.A. (1997). Enhancement of DNA repair in human skin cells by thymidine dinucleotides: evidence for a p53-mediated mammalian SOS response. Proc. Natl. Acad. Sci. U. S. A. 94, 12627-12632. (Pubitemid 27492579)
4. 0 overhang-specific DNA. Exp. Cell Res. 276, 185-193. (Pubitemid 34969312)
5. ELLER, M.S., YAAR, M., and GILCHREST, B.A. (1994). DNA damage and melanogenesis. Nature 372, 413-414.
6. FREW, A.J., LINDEMANN, R.K., MARTIN, B.P., CLARKE, C.J.P., SHARKEY, J., ANTHONY, D.A., BANKS, K.-M., HAYNES, N.M., GANGATIRKAR, P., STANLEY, K., BOL-DEN, J.E., TAKEDA, K., YAGITA, H., SECRIST, J.P., SMYTH, M.J., and JOHNSTONE, R.W. (2008). Combination therapy of established cancer using histone deacetylase inhibitor and TRAIL receptor agonist. Proc. Natl. Acad. Sci. U. S. A. 105, 11317-11322.
7. GEORGE, P., BALI, P., ANNAVARAPU, S., SCUTO, A., FIS-KUS, W., GUO, F., SIGUA, C., SONDARVA, G., MOSCINSKI, L., ATADJA, P., and BHALLA, K. (2005). Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 105, 1768-1776. (Pubitemid 40223701)
8. GOUKASSIAN, D.A., BAGHERI, S., EL KEEB, L., ELLER, M.S., and GILCHREST, B.A. (2002). DNA oligonucleotide treatment corrects the age-associated decline in DNA repair capacity. FASEB J. 16, 754-756.
9. GUARNERI, V., PIACENTINI, F., BARBIERI, E., and CONTE, P.F. (2010). Achievements and unmet needs in the management of advanced ovarian cancer. Gynecol. Oncol. 117, 152-158.
10. KARLSEDER, J., BROCCOLI, D., DAI, Y., HARDY, S., and DE LANGE, T. (1999). p53- and ATM-dependent apoptosis induced by telomeres lacking TRF2. Science 283, 1321-1325.
11. 0 overhang sequence induces senescence. Proc. Natl. Acad. Sci. U. S. A. 100, 527-531. (Pubitemid 36126085)
12. LI, G.Z., ELLER, M.S., HANNA, K., and GILCHREST, B.A. (2004). Signaling pathway requirements for induction of senescence by telomere homolog oligonucleotides. Exp. Cell Res. 301, 189-200. (Pubitemid 39504972)
13. LIU, J., and MATULONIS, U.A. (2010). New advances in ovarian cancer. Oncology 24, 721-728.
14. LONGE, H.O., ROMESSER, P.B., RANKIN, A.M., FALLER, D.V., ELLER, M.S., GILCHREST, B.A., and DENIS, G.V. (2009). Telomere homolog oligonucleotides induce apoptosis in malignant but not in normal lymphoid cells: mechanism and therapeutic potential. Int. J. Cancer 124, 473-482.
15. OHASHI, N., YAAR, M., ELLER, M.S., TRUZZI, F., and GILCHREST, B.A. (2007). Features that determine telomere homolog oligonucleotide-induced therapeutic DNA damagelike responses in cancer cells. J. Cell. Physiol. 210, 582-595. (Pubitemid 46185027)
16. PURI, N., ELLER, M.S., BYERS, H.R., DYKSTRA, S., KUBERA, J., and GILCHREST, B.A. (2004). Telomere-based DNA damage responses: a new approach to melanoma. FASEB J. 18, 1373-1381. (Pubitemid 39150352)
17. RANKIN, A.M., FALLER, D.V., and SPANJAARD, R.A. (2008). Telomerase inhibitors and "T-oligo" as cancer therapeutics: contrasting molecular mechanisms of cytotoxicity. Anticancer Drugs 19, 329-338.
18. SAITO, A., YAMASHITA, T., MARIKO, Y., NOSAKA, Y., TSU-CHIYA, K., ANDO, T., SUZUKI, T., TSURUO, T., and NAKA-NISHI, O. (1999). A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl. Acad. Sci. U. S. A. 96, 4592-4597. (Pubitemid 29190381)
19. SARKAR, S., SVOBODA, M., DE BEAUMONT, R., and FREEDMAN, A.S. (2002). The role of Akt and RAFTK in beta1 integrin mediated survival of precursor B-acute lymphoblastic leukemia cells. Leuk. Lymphoma 43, 1663-1671. (Pubitemid 34823488)
20. TAKAI, N., and NARAHARA, H. (2010). Histone deacetylase inhibitor therapy in epithelial ovarian cancer. J. Oncol. 2010, 458431.
21. VAZIRI, C., and FALLER, D.V. (1995). Repression of platelet-derived growth factor beta-receptor expression by mitogenic growth factors and transforming oncogenes in murine 3T3 fibroblasts. Mol. Cell. Biol. 15, 1244-1253.
22. YAAR, M., ELLER, M.S., PANOVA, I., KUBERA, J., WEE, L.H., COWAN, K.H., and GILCHREST, B.A. (2007). Telomeric DNA induces apoptosis and senescence of human breast carcinoma cells. Breast Cancer Res. 9, R13.